Pulsatile drug delivery systems (PDDS) are gaining significant attention in pharmaceutical research because they deliver drugs at a predetermined time after a specific lag period, thereby synchronizing drug release with the body’s circadian rhythm. Perindopril Erbumine is an angiotensin-converting enzyme inhibitor widely used in the management of hypertension and cardiovascular disorders. Conventional dosage forms may not provide optimal therapeutic outcomes due to fluctuations in blood pressure during early morning hours. Modified Pulsincap technology offers a promising approach for chronotherapeutic delivery of Perindopril Erbumine by releasing the drug after a programmed lag time. The present review discusses the principles, rationale, formulation approaches, mechanism, advantages, evaluation parameters, and applications of pulsatile drug delivery systems with special emphasis on modified Pulsincap technology for Perindopril Erbumine.
Gangidi Sireesha*1, Dr. Chandra Shekara Rao Baru2, Balmoni Shivani3, Ganji Sree Ramya4, Jellla Ruchitha5, Kummari Poojitha6, Ruksar Jahan7 (Mon,) studied this question.